Publicacións en colaboración con investigadores/as de Gustave Roussy Cancer Campus (13)

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

  2. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer

    Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8

  3. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

    European Journal of Cancer, Vol. 208

  4. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356

  5. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

2023

  1. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

    Nature Reviews Clinical Oncology, Vol. 20, Núm. 10, pp. 664-677

  2. MET alterations in NSCLC—Current Perspectives and Future Challenges

    Journal of Thoracic Oncology, Vol. 18, Núm. 4, pp. 419-435

  3. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

    JTO Clinical and Research Reports, Vol. 4, Núm. 1

  4. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

    Annals of Oncology, Vol. 34, Núm. 5, pp. 468-476

  5. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

    Annals of Oncology, Vol. 34, Núm. 10, pp. 920-933

  6. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

    Lung Cancer, Vol. 178, pp. 116-122

2022

  1. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer

  2. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer, Vol. 167, pp. 142-148